 Advaxis Inc NASDAQ: ADXS announced updated data from its Phase 12 study evaluating ADXS-503 in combination with Merck Co Incs Keytruda pembrolizumab in patients with metastatic non-small-cell lung cancer NSCLC. Data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting. 